ArticleAnnals of medicine and surgery (2012)2026
Antihyperglycemic and antioxidant potential of
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The research aimed to access the antihyperglycemic and antioxidant properties of the methanolic extract of Objective: The objective aims to examine the effects of MECC on fasting blood glucose (FBG), glucose tolerance, antioxidant enzyme activity, lipid peroxidation, and histopathological alterations in the liver and kidneys of diabetic mice. Method: Male Swiss albino mice were categorized into normal untreated control, diabetic untreated control, and diabetic + ascorbic acid-treated, diabetic + MECC treated (350 mg/kg body weight [b.w.]). Diabetes was induced using STZ, and the effects of MECC were assessed through FBG, intraperitoneal glucose tolerance tests, and measurement of oxidative stress markers such as thiobarbituric acid reactive Substances (TBARS), superoxide dismutase (SOD), and catalase (CAT). Histopathological analysis of kidney and liver tissues was performed to evaluate tissue damage and recovery. Results: MECC treatment at 350 mg/kg b.w. significantly decreased the FBG levels in diabetic control mice, with effects comparable to standard antihyperglycemic drugs like metformin and glibenclamide. Glucose tolerance was notably improved, and oxidative stress markers, including TBARS, were normalized in treated groups. Antioxidant enzyme activity (SOD and CAT) was restored in the liver and kidneys. Histopathological analysis revealed substantial recovery of tissue architecture, with nearly normal glomeruli and hepatocytes in diabetic-MECC-treated mice, indicating protection against diabetes-induced damage. Conclusion: MECC demonstrated potent antihyperglycemic, antioxidant, and tissue-protective effects in diabetic mice, suggesting its capability as a treatment option for diabetes management. Further evaluation is needed to investigate its potential clinical uses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.